Cytomedix Appoints Dr. Craig Mendelsohn to Board of Directors

Cytomedix Appoints Dr. Craig Mendelsohn to Board of Directors
Gains Industry Veteran with Legal and Regulatory Affairs Expertise

ROCKVILLE, Md. (November 13, 2009) - Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the appointment of Craig B. Mendelsohn, M.D., J.D. to the Company's Board of Directors, increasing the number of board members to seven.

Dr. Mendelsohn, age 55, is Vice President and Deputy General Counsel for the American Red Cross.  He brings to Cytomedix more than 15 years of healthcare industry experience as a regulatory attorney and medical director in the medical device and pharmaceutical industries.  Dr. Mendelsohn has significant FDA expertise with a focus on medical device law, legal affairs and regulatory affairs.

"We are very fortunate that Dr. Mendelsohn has agreed to join our Board," said Martin Rosendale, Chief Executive Officer of Cytomedix. "Dr. Mendelsohn's impressive track record and knowledge of the clinical, legal and regulatory landscape for medical device companies - specifically with regard to blood and plasma products - will be of tremendous value to Cytomedix as we build the company into a leading player in the regenerative medicine field."

"I am delighted to join Cytomedix at this time of significant growth and evolution for the Company.  Chronic wounds are a serious health problem worldwide, and I look forward to working with the Cytomedix team to bring innovative solutions to these clinical challenges," commented Dr. Mendelsohn.

At the American Red Cross, Dr. Mendelsohn is responsible for managing and leading a staff of attorneys that provide counsel to the Biomedical Services division at the organization, while providing guidance and legal counsel to executive management and the Board of Governors.
Previously, he held senior-level Medical Director and Regulatory Affairs positions for a number of medical device and pharmaceutical companies including Cardinal Health, Core Dynamics and ZLB Bioplasma, as well as at the Plasma Protein Therapeutics Association.  Dr. Mendelsohn began his legal career in 1994 at the Washington, D.C. headquarters of Hogan & Hartson, an international full-service law firm, as a member of the Food, Drug, Agriculture, and Medical Devices Group.  Dr. Mendelsohn also had a private practice in ophthalmology for ten years prior to obtaining his law degree.

Dr. Mendelsohn received his Juris Doctor, Cum Laude from Georgetown University Law Center, his Doctor of Medicine from George Washington University Medical Center, and his Bachelor of Arts in Chemistry from Emory University.  He is co-author on a number of papers in both clinical and legal publications.

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.